Aethlon Medical Receives HREC's Nod for Hemopurifier Cancer Trial

Aethlon Medical, Inc., a medical therapeutic company dedicated to creating products to treat cancer and life-threatening infectious illnesses, declared that the Human Research Ethics Committee (HREC) of the Central Adelaide Local Health Network (CALHN) granted full ethical authorization for Aethlon's safety, feasibility, and dose-finding clinical trial of the Hemopurifier in cancer patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy. 

The approval lasts for three years, ending June 13, 2027. Prof. Michael Brown and his team will perform the trial at the Cancer Clinical Trials Unit, CALHN, Royal Adelaide Hospital in Adelaide, Australia.

"The approval from the Human Research Ethics Committee at Central Adelaide Local Health Network marks a significant milestone for Aethlon, as they deemed that our clinical study meets the requirements of the Australia's National Statement on Ethical Conduct in Human Research," stated Steven LaRosa, MD, chief medical officer of Aethlon Medical. "We look forward to working closely with Prof. Brown and his staff, and with our Contract Research Organizations, NAMSA and ReSQ Clinical Research. The next steps include submission to the Therapeutic Goods Administration, the national health regulatory agency of Australia, obtaining approval from the CALHN Research Governance Committee, and conducting a site initiation visit to facilitate patient enrollment. Following this Ethics Board approval, we plan to submit to the Ethics Committees at two additional sites in Australia and one in India."